GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (STU:J75) » Definitions » Capex-to-Operating-Income

Kineta (STU:J75) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kineta Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Kineta's Capital Expenditure for the three months ended in Mar. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-5.89 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Kineta Capex-to-Operating-Income Historical Data

The historical data trend for Kineta's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta Capex-to-Operating-Income Chart

Kineta Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
- - - -

Kineta Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kineta's Capex-to-Operating-Income

For the Biotechnology subindustry, Kineta's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kineta's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Kineta's Capex-to-Operating-Income falls into.



Kineta Capex-to-Operating-Income Calculation

Kineta's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -14.418
=N/A

Kineta's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -5.894
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kineta  (STU:J75) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Kineta Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Kineta's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Kineta (STU:J75) Business Description

Industry
Traded in Other Exchanges
Address
219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Kineta (STU:J75) Headlines

No Headlines